Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 19, 2022 16:01 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer

TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases,...
May 31, 2022 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Participate in the Jefferies Healthcare Conference

TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
May 17, 2022 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV,...
May 10, 2022 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17

TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for...
May 03, 2022 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May

TEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for...
April 28, 2022 16:05 ET | Source: VBL Therapeutics

VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TEL AVIV, Israel and NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
April 26, 2022 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer

FDA grants Fast Track designation to facilitate development and expedite the review of therapies with potential to treat serious unmet medical needs. The purpose of this designation is to bring...
March 31, 2022 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer

Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian cancer Event on Monday, April 11, 2022 at 12pm EDT in New York City TEL AVIV, Israel and...
March 23, 2022 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update

OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023...
March 14, 2022 09:57 ET | Source: VBL Therapeutics

UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23

TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for...